Drug trial targets debilitating bleeding disorder

This study is testing whether the drug bevacizumab can help control chronic bleeding and severe anemia in adults with Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that causes fragile, abnormal blood vessels. Participants receive the drug for 24 weeks while researchers measure changes in their need for blood transfusions, iron infusions, and the severity of nosebleeds. The goal is to see if this treatment can better manage the symptoms of HHT and improve patients' quality of life.